



# First Seminar of Medicinal & Natural Products Chemistry

Shiraz, Iran. May 10-11, 2005



S47

## Synthesis of Novel Leflunomide Analogues as Antirheumatic Agents

*Elham Saber Farimani<sup>1</sup>, Farzin Hadizadeh<sup>1,2</sup>*

<sup>1</sup>Pharmaceutical Sciences Research Center, MUMS, Mashhad, Iran

<sup>2</sup>Pharmacy Faculty, MUMS, Mashhad, Iran

Leflunomide, 5-methyl-N-[4-(trifluoromethyl)phenyl]-4-isoxazolecarboxamide, is a dihydroorotate dehydrogenase inhibitors which is used in the treatment of rheumatoid arthritis. In this project we replaced methylisoxazolyl moiety in leflunamide with bioisosteric group 2-alkylthio-1-benzyl-5-imidazolyl.

Starting from benzylamine hydrochloride (1) and dihydroxyacetone, 1-benzyl-2-mercapto-5-hydroxymethylimidazole (2) was synthesized. Compound 2 was alkylated with RX to give 2-alkylthio-1-benzyl-5-hydroxymethylimidazole (3). Oxidation of 3 with MnO<sub>2</sub> gave aldehyde (4). Further oxidation of 4 with silver oxide gave corresponding carboxylic acid (5). Compound 5 was converted to its acid halide (6) with thionyl chloride, which was reacted with 4-trifluoromethylaniline to give the title 1-alkylthio-2-benzyl-N-[4-(trifluoromethyl)phenyl]-5-imidazolecarboxamide (7).

All the title compounds and intermediates were determined by spectroscopic methods including NMR and IR.